What Is Islet Cell Transplantation?

Islet cell transplantation is a specialized procedure that offers an alternative to traditional insulin therapy for people with Type 1 diabetes. The technique involves isolating insulin-producing islet cells from a deceased donor pancreas and infusing them into the recipient's liver. Once lodged in the liver's blood vessels, these cells begin to produce insulin, helping to restore the body's ability to regulate blood glucose naturally. This approach has evolved over decades, with the first successful human islet transplants reported in the late 1980s. Since then, refinements in cell isolation, immunosuppression protocols, and patient selection have steadily improved outcomes. Today, islet cell transplantation is performed at select medical centers worldwide, often as part of clinical trials or for patients who meet strict eligibility criteria.

How the Procedure Works

The procedure begins with the careful procurement of a donor pancreas, which is processed in a specialized laboratory. Enzymes digest the organ to release the islets—clusters of cells that contain beta cells responsible for insulin secretion. After purification, the islets are assessed for viability and quantity. The transplant itself is performed under local anesthesia with sedation. A catheter is inserted into the portal vein (usually through a small abdominal incision), and the islet cell preparation is infused. The cells travel to the liver and implant in its small blood vessels, where they begin sensing blood sugar levels and releasing insulin. The entire infusion typically takes 30–60 minutes, and patients are monitored closely for complications such as bleeding or portal vein thrombosis.

Benefits of Islet Cell Transplantation for Type 1 Diabetes

Improved Blood Sugar Control

One of the most immediate and measurable benefits is a marked reduction in glycemic variability. Patients who achieve sustained islet function experience fewer episodes of severe hypoglycemia—a dangerous and potentially life-threatening complication of Type 1 diabetes. Continuous glucose monitoring data often show a significant increase in time-in-range, with many patients maintaining blood glucose levels between 70 and 180 mg/dL for more than 80% of the day. This stabilization is largely due to the graft's ability to secrete insulin in response to real-time glucose fluctuations, a feature that exogenous insulin injections cannot fully replicate.

Reduced or Eliminated Insulin Requirements

A substantial proportion of recipients become insulin-independent in the months following transplantation. The Clinical Islet Transplantation Consortium has reported that approximately 50% of patients achieve insulin independence one year after transplant, with some remaining free of injections for several years. Even partial graft function can dramatically reduce daily insulin doses, making diabetes management easier and decreasing the burden of multiple daily injections. For patients who do need some supplemental insulin, the overall dose is often much lower than before transplantation, leading to fewer injection sites and less injection-related discomfort.

Enhanced Quality of Life

Beyond the numbers on a glucometer, islet cell transplantation can transform daily living. Freedom from the constant vigilance required for intensive insulin therapy—counting carbohydrates, adjusting doses, and worrying about hypoglycemia—is a powerful motivator for many patients. Studies consistently show improvements in physical functioning, emotional well-being, and social interactions after successful transplantation. The reduction in diabetes distress, anxiety about severe lows, and burden of frequent monitoring often leads to greater participation in work, exercise, and leisure activities. The National Health Service (NHS) in the UK notes that many recipients describe the procedure as life-changing.

Protection Against Long-Term Complications

Better glucose control is known to reduce the risk of diabetic complications such as retinopathy, nephropathy, and neuropathy. While long-term data on islet transplantation are still accumulating, early evidence suggests that sustained normoglycemia can slow or halt the progression of some microvascular complications. A study in Diabetes Care (linked below) found that patients with functioning grafts for three years or more showed stable or improved renal function and less progression of diabetic retinopathy compared to matched control groups on insulin therapy. This protective effect reinforces the potential for islet cell transplantation to alter the natural history of Type 1 diabetes.

Risks and Challenges of Islet Cell Transplantation

Immunological Rejection

The body's immune system recognizes the transplanted islet cells as foreign and mounts an attack. To prevent rejection, patients must take lifelong immunosuppressive drugs. Despite these medications, a proportion of grafts eventually fail due to immune-mediated injury, either from recurrence of autoimmunity against beta cells or from alloreactivity against donor cells. Even with modern immunosuppression, the five-year insulin independence rate hovers around 30–50%, with many patients requiring a second or third islet infusion to maintain adequate function. Close monitoring of graft function through C-peptide levels and blood glucose is essential, and rescue islet transplants are sometimes necessary.

Side Effects of Immunosuppressive Drugs

Immunosuppressants used in islet transplantation typically include a combination of tacrolimus, sirolimus, or mycophenolate mofetil, often with an induction agent like antithymocyte globulin. These drugs carry significant side effects: increased susceptibility to infections (from viral reactivations to opportunistic infections), elevated blood pressure and cholesterol, kidney toxicity, mouth ulcers, and gastrointestinal disturbances. The risk of certain cancers, such as lymphoma and skin cancer, is also elevated with long-term immunosuppression. Patients must weigh these risks against the benefits of improved diabetes control. Regular screening for infections, routine laboratory monitoring, and dose adjustments are part of the lifelong care required.

Limited Donor Availability and Organ Allocation

Isolated human islets come from deceased donor pancreases, which are scarce globally. In many countries, whole pancreas transplantation takes priority in organ allocation, and only islets from pancreases deemed unsuitable for whole organ transplant are used for islet isolation. This limits the number of procedures that can be performed. Moreover, not every pancreas yields enough viable islets for a successful transplant; often, islets from two or more donors are required to achieve insulin independence. This scarcity, combined with the need for a perfect blood type match and low levels of preformed antibodies, makes islet transplantation available only to a small subset of patients with Type 1 diabetes.

Variable and Uncertain Long-Term Outcomes

Outcomes vary widely among recipients. While some maintain robust graft function for more than a decade, others experience gradual loss of insulin production within the first year. Factors influencing durability include the number and quality of islets transplanted, immunosuppressive regimen, and the patient's underlying autoimmune activity. The rate of insulin independence declines over time, and many patients eventually return to insulin therapy, albeit often at lower doses. This variability makes it difficult for clinicians to guarantee long-term success, and patients must have realistic expectations. Ongoing research aims to identify biomarkers that predict graft survival and to develop strategies to prolong function.

Who Is a Candidate for Islet Cell Transplantation?

Islet cell transplantation is not suitable for every person with Type 1 diabetes. Strict selection criteria are applied to maximize benefits and minimize risks. Typical candidates include adults (often between the ages of 18 and 65) with Type 1 diabetes who experience frequent, severe, and unpredictable episodes of hypoglycemic unawareness—despite optimized insulin therapy. Also considered are those with labile glucose control that severely impairs quality of life, or those who have undergone a previous kidney transplant and are already on immunosuppression. Exclusion criteria include active infections, significant liver disease, uncontrolled cardiovascular disease, obesity (BMI > 30), and psychiatric conditions that could interfere with long-term follow-up. A comprehensive evaluation by a multidisciplinary team—including endocrinologists, transplant surgeons, dietitians, and psychologists—is required before listing a patient for the procedure. The JDRF (Juvenile Diabetes Research Foundation) provides detailed information on eligibility and centers that offer the treatment.

Comparing Islet Cell Transplantation to Whole Pancreas Transplantation

Whole pancreas transplantation (WPT) is another option for selected patients with Type 1 diabetes, often performed simultaneously with kidney transplantation in cases of end-stage renal disease. WPT carries a higher surgical risk due to its complexity, including risks of graft thrombosis, pancreatitis, and anastomotic leaks. However, it typically provides more durable insulin independence and does not require the islet isolation process. Islet cell transplantation, by contrast, is a minimally invasive procedure with lower acute surgical morbidity. It can be repeated if needed and can be offered to patients who are not candidates for major surgery. The choice between the two should be individualized, balancing the patient's surgical risk, the availability of donor organs, and the expected outcomes. Current guidelines from the Organ Procurement and Transplantation Network recommend islet transplantation only for patients with severely labile diabetes and no contraindications to immunosuppression.

Future Directions and Ongoing Research

Researchers are actively working to overcome the limitations of islet transplantation. Key areas include:

  • Encapsulation technologies: Enclosing islets in a protective, semipermeable membrane that shields them from immune attack while allowing glucose and insulin to pass through. This could eliminate the need for systemic immunosuppression. Clinical trials are underway using devices implanted under the skin or in the peritoneal cavity.
  • Alternative islet sources: Developing insulin-producing cells from stem cells (induced pluripotent stem cells or embryonic stem cells) offers a theoretically unlimited supply. Vertex Pharmaceuticals recently reported promising results from a trial using stem cell-derived islets in a patient with Type 1 diabetes, showing measurable C-peptide production and reduced insulin needs.
  • Xenotransplantation: Using islets from genetically modified pigs that are less likely to be rejected. This could address donor shortage if safety and efficacy are proven in human trials.
  • Improved immunosuppression with fewer side effects, such as co-stimulation blockade agents (e.g., belatacept) that are less nephrotoxic, or promoting immune tolerance through regulatory T cell therapy.
  • Cell replacement without transplantation: Some researchers are investigating whether beta cell regeneration can be stimulated in the patient's own pancreas, though this approach is still in early stages.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) continues to fund research to improve graft survival and expand access to islet transplantation.

Conclusion

Islet cell transplantation offers a powerful tool for managing Type 1 diabetes in selected patients, providing improved glucose control, reduced insulin dependence, and enhanced quality of life. However, it is not a cure and comes with significant risks, primarily lifelong immunosuppression and variable long-term graft survival. The decision to pursue this therapy must be made collaboratively between the patient and a specialized transplant team, with careful consideration of individual circumstances and expectations. As research progresses—especially in stem cell biology, immunomodulation, and bioengineering—the future may hold safer and more widely accessible cell-based therapies that could transform the management of Type 1 diabetes for millions around the world. For now, islet cell transplantation remains a valuable, albeit limited, option that continues to evolve and improve. Further reading and updates on clinical trial eligibility can be found through the ClinicalTrials.gov database and major diabetes research organizations.